Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways

Br J Pharmacol. 2013 Nov;170(5):1078-91. doi: 10.1111/bph.12333.

Abstract

Background and purpose: The gallnut of Rhus chinensis MILL and its main constituent penta-O-galloyl-β-D-glucose (PGG) inhibited NF-κB activation in LPS-stimulated peritoneal and colonic macrophages. Here we have investigated PGG mechanisms underlying anti-inflammatory effects of PGG in vitro and in vivo.

Experimental approach: Male C57BL/6 mice (18-22 g, 6 weeks old) were used to prepare peritoneal and colonic macrophages and for the induction of colitis by intrarectal administration of 2,3,4-trinitrobenzene sulphonic acid (TNBS). A range of inflammatory markers and transcription factors were evaluated by elisa, immunoblotting, flow cytometry and confocal microscopy.

Key results: Expression of Toll-like receptor (TLR)-4 or Lipopolysaccharide (LPS) binding to TLR-4 in LPS-stimulated peritoneal macrophages was not affected by PGG. However PGG inhibited binding of an anti-MyD88 antibody to peritoneal macrophages, but did not reduce binding of anti-IL-1 receptor-associated kinase (IRAK1) and IRAK4 antibodies to the macrophages with or without transfection with MyD88 siRNA. PGG potently reduced the activation of IRAK1, NF-κB, and MAPKs in LPS- or pepetidoglycan-stimulated peritoneal and colonic macrophages. PGG suppressed IL-1β, TNF-α and IL-6 in LPS-stimulated peritoneal macrophages, while increasing expression of the anti-inflammatorycytokine IL-10. Oral administration of PGG inhibited colon shortening and myeloperoxidase activity in mice with TNBS-induced colitis, along with reducing NF-κB activation and IL-1β, TNF-α, and IL-6 levels, whereas it increased IL-10.

Conclusions and implications: PGG reduced activation of NF-κB and MAPK signalling pathways by directly interacting with the MyD88 adaptor protein. PGG may ameliorate inflammatory diseases such as colitis.

Keywords: MyD88; NF-κB; inflammation; macrophage; penta-O-galloyl-β-D-glucose.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology*
  • Cells, Cultured
  • Colitis / chemically induced
  • Colitis / enzymology
  • Colitis / immunology
  • Colitis / prevention & control*
  • Colon / drug effects*
  • Colon / enzymology
  • Colon / immunology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / pharmacology*
  • Hydrolyzable Tannins / administration & dosage
  • Hydrolyzable Tannins / pharmacology*
  • Inflammation Mediators / metabolism
  • Interleukin-1 Receptor-Associated Kinases / metabolism
  • MAP Kinase Signaling System / drug effects*
  • Macrophages, Peritoneal / drug effects*
  • Macrophages, Peritoneal / enzymology
  • Macrophages, Peritoneal / immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinases / metabolism
  • Molecular Sequence Data
  • Myeloid Differentiation Factor 88 / antagonists & inhibitors*
  • Myeloid Differentiation Factor 88 / genetics
  • Myeloid Differentiation Factor 88 / metabolism
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism
  • Phosphorylation
  • RNA Interference
  • Toll-Like Receptor 4 / metabolism
  • Transfection
  • Trinitrobenzenesulfonic Acid

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Hydrolyzable Tannins
  • Inflammation Mediators
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • pentagalloylglucose
  • Trinitrobenzenesulfonic Acid
  • Interleukin-1 Receptor-Associated Kinases
  • Irak1 protein, mouse
  • Mitogen-Activated Protein Kinases

Associated data

  • GENBANK/A23187